Biosynth, a supplier of critical materials to the life science industry, has acquired Pepceuticals, a UK producer of synthetic peptides with multi-kilogramme GMP facilities and fill-finish capabilities designed to support customers from clinical trials to commercial supply.

Biosynth, headquartered in Staad, Switzerland, supplies the pharmaceutical and diagnostic sectors with critical materials for research. The company has a research product portfolio of over a million products. It offers end-to-end manufacturing services. Its expertise and capability spans complex chemicals, peptides, and key biologics

Commenting on the acquisition, Dr Urs Spitz, CEO and President of Biosynth, said: “We are very excited for Pepceuticals to be joining Biosynth. The Pepceuticals team has great expertise in optimizing the production of peptides and working at GMP and larger scales, making it a natural fit for Biosynth as we round out our peptide offering.”

Ehab Alramahy, Senior Vice President, Head of Peptide Division, added: “The acquisition of Pepceuticals into the Biosynth family strengthens our position in the peptide field. As we’ve built the peptide division, our goal has always been to offer a seamless, comprehensive service to our customers. The acquisition represents an important step which allows us to extend our support to clinical trials and commercial supply.”

Dr Kamal Badiani, Managing Director of Pepceuticals, commented: “Joining the Biosynth Group marks the start of an exciting chapter for our team. We look forward to working together, combining our expertise and enhancing our offering to our customers. We are excited to join Biosynth and provide leading peptide manufacturing services.”